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Abstract
Understanding the molecular basis of human disease is one of the greatest challenges of
our time, and recent explosion in genetic and genomic datasets are finally putting it within
reach. In the last ten years, genome-wide association studies have identified thousands
of genetic variants associated with disease. However, the majority of these variants fall
outside genes making interpreting their role in disease difficult. In parallel, the ENCODE
and Roadmap Epigenomics consortia have produced high resolution annotations of the
genome which identify large portions with potential regulatory function. We develop
methods to interpret genome-wide association studies using these annotations to generate
hypotheses about how associated variants contribute to disease mechanism. In particu-
lar, we go beyond the usual stringent p-value threshold to investigate variants with small
individual effect sizes which current methods do not have power to detect. Evaluating
our methods on the Wellcome Trust Case Control Consortium 7 Disease studies, we find
associated variants are enriched in a variety of functional categories even after control-
ling for various biases. We also find an unprecedented number of variants contribute to
this enrichment, supporting our hypothesis that the architecture of these diseases involves
combinatorial interaction of many variants with small individual effect sizes.
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Chapter 1
Introduction
Understanding the molecular basis of human disease is one of the greatest challenges of
our time, and recent explosion in genetic and genomic datasets are finally putting it within
reach. In the last ten years, genome-wide association studies (GWAS) have identified thou-
sands of genetic variants associated with disease. However, the majority of these variants
fall outside genes making interpreting their role in disease difficult. The first step in go-
ing from GWAS to explaining disease is to generate high quality hypotheses about which
disease-associated variants are causal and how they contribute to the disease mechanism.
The difficulty up to this point has been a lack of understanding of the non-coding genome.
The ENCODE and Roadmap Epigenomics consortia have now produced high res-
olution annotations of the genome which identify large portions with potential regula-
tory function. In particular, ChromHMM learns combinations of chromatin modifications
which are enriched in regions with particular function. Annotating the genome with the
most likely hidden state at each point gives an unparalleled resource for interpreting non-
coding variants. Indeed, current work has begun to show top GWAS hits fall dispropor-
tionately in regulatory regions. It is now possible link these regions to their target genes
and determine the proteins they recruit to regulate their targets and where they bind. With
these rich annotations in hand current work can more confidently identify causal variants
and generate highly specific mechanistic hypotheses about their contribution to disease
pathology.
However, it is also known that GWAS lacks sufficient power to detect all but the most
deleterious variants due to small sample sizes and human population genetic biases. The
next key challenge in understanding complex polygenic disease is identifying causal vari-
ants in the long tail of the p-value distribution.
The goals of this thesis are three-fold. The first is to develop methods to use reg-
ulatory annotations and investigate the whole spectrum of GWAS p-values rather than
only the top hits which pass the usual p-value threshold. We hypothesize complex traits
arise from large numbers of variants with small individual effect sizes. These variants es-
cape detection because typical p-value cutoffs are too stringent and samples sizes are not
large enough. However, the ranking of SNPs by association to trait still gives some par-
tial information which should contribute to genome-wide trends of over-representation in
functional regions of the genome.
The second goal is to apply these methods to GWAS data studying Type 1 Diabetes
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(T1D) and identify variants which are enriched. In particular, we should identify variants
beyond the usual stringent p-value threshold which have smaller effect sizes. We also aim
to identify relevant regulatory regions and the cell types which they are active in.
The third goal is to interpret the role of identified variants in disease. We should
be able to make mechanistic hypotheses about how the variants we identify contribute
to the disease. In particular, we look for gene pathways which are enriched for disease-
associated variants.
The contributions of this thesis are two-fold. First, the methods should be generally
applicable to complex polygenic traits. They should give some insight which will direct
further investigation on the genetic architecture of these traits. Second, our results on
T1D should reveal new insights about the disease biology which could be used to develop
predictive models, diagnostics, and potential treatments.
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Chapter 2
Background information
2.1 Inheritance
Near the turn of the 2 0th century, researchers rediscovered the work of Gregor Mendel,
whose experiments on peas elucidated the particulate nature of inheritance. This work
became the basis of the nascent field of genetics. But it took another half century for
Watson and Crick to discover the molecular basis of inheritance, the double helical poly-
mer deoxyribonucleic acid (DNA) [46]. DNA is a polymer of nucleotides (or bases): adenine,
thymine, guanine, and cytosine (represented "A", "T", "G", "C"). The four nucleotides ap-
pear in two complementary pairs due to hydrogen bonding: adenine with thymine and
guanine with cytosine. The primary sequence is paired with its reverse complement in the
double helix structure. DNA is further structured into discrete molecules called chromo-
somes.
By the 19th century, scientists had already observed the role of DNA in asexual repro-
duction. In the process of mitosis, enzymes replicate the DNA exactly and divide the two
copies among the two daughter cells. In the late 1800s, researchers observed the process
of meiosis which is required for sexual reproduction. Diploid organisms (such as humans)
have two homologous copies of each chromosome. However, they produce haploid cells
(which only have one copy) called gametes which combine in the process of fertilization to
produce a new diploid organism. Meiosis is initially identical to mitosis. However, after
two diploid cells are produced each immediately divides into two haploid cells.
2.2 Genes and regulation
DNA is often called the "genetic code". In particular, regions of the sequence called genes
are transcribed into ribonucleic acid (RNA). RNA is a single-stranded polymer similar to
DNA, but substituting the nucleotide uracil for thymine. While DNA is confined to the
nucleus of the cell, RNA can move out of the nucleus. Outside of the nucleus, cell machin-
ery translates RNA into proteins. Codons (words of length 3) in the DNA/RNA sequence
correspond to amino acids, the building blocks of proteins.
There are two key observations to make about this code. First, we now know less
than 2% of the genome codes for proteins (although significantly more is transcribed into
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Figure 2.1: Illustration of regulatory regions and mechanisms [7]. The primary sequence
(bottom) contains transcribed regions such as genes whose expression is regulated at short-
range by promoters and long-range by enhancers. Transcription factors bind to the se-
quence and can form large complexes (center). The DNA molecule itself undergoes chemi-
cal modifications (top left) and changes conformation (top right) to change the accessibility
of the primary sequence.
RNA). Second, every cell in complex organisms such as humans contains the same primary
sequence of DNA. These observations raise the question of why we observe a huge variety
of human cell types with diverse physical traits and functions.
We now know there is more encoded in the DNA sequence than just proteins. An-
other portion of the genome has regulatory function, modulating the expression (level of
transcription) of genes. Figure 2.1 shows a variety of regulatory regions. Promoters are
directly upstream of genes and are responsible for recruiting the transcription factors (TFs)
which transcribe DNA. The structure of TFs is such that they bind to specific DNA se-
quence motifs (short words of length 8-16). TFs can also recruit other TFs to form larger
complexes which are necessary to start transcription of some genes. More distant regions
called enhancers also recruit TFs through motifs. TFs bound to enhancers can interact with
promoters and genes because the DNA molecule can fold to bring these regions close to-
gether.
It is important to note genes both produce proteins and are regulated by proteins.
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Indeed, there is a complex network of interactions between genes and regulators. The
output of one gene may be a regulator which targets another, related gene. Larger gene
pathways are sets of related or linked genes which together contribute to a coherent cell
function.
2.3 Linkage analysis
In 1911, Morgan observed crossover recombination in D. melanogaster (fruit fly) meiosis. In
one phase of meiosis, the chromosomes are arranged in the middle of the cell. During
this phase, homologous chromosomes can cross over each other and exchange contigu-
ous subsequences of DNA. Morgan realized the frequency of crossover recombination be-
tween two points on a chromosome was proportional to the distance between them. Thus,
Mendel's hypothesis genes were inherited independently was wrong. This phenomenon,
where genes are inherited together, is called linkage disequilibrium (LD). In 1913, Morgan
and Sturtevant used this observation to develop the first linkage map and localized genes
driving fly phenotypes (traits). Such a map gives not only the order of genes on the chromo-
some but also their relative distance to each other. A distance of 1 centimorgan corresponds
to a .01 probability of recombination between two points on the chromosome.
Figure 2.2 shows linkage disequilibrium patterns for a region of chromosome 5. Pair-
wise LD is visualized as a lower-triangular matrix, where each point corresponds to a pair
of SNPs and the amount of red represents the strength of correlation. Strong LD patterns
are outlined in black and demarcate blocks of nearby SNPs which are only rarely separated
by recombination.
Linkage analysis is the problem of finding DNA variation which cosegregates (is inher-
ited together) with a trait of interest. If the DNA variant is inherited along with the trait,
it must lie close or be "linked" to the gene driving the trait because recombination was
not observed to separate the two. In the late 1970s, methods for cloning [20] and sequenc-
ing [32] DNA made it possible to tie linkage maps to the underlying sequence and clone
linked genes. However, building genome-wide linkage maps in human was infeasible
because few genetic markers (known positions on a chromosome) were known.
In 1980, Botstein proposed using restriction fragment length polymorphisms to build link-
age maps [3]. Restriction enzymes are proteins which cut DNA at specific sequence motifs.
Applying a restriction enzyme to the whole genome gives a particular distribution of frag-
ment lengths. Variations in the sequence can either remove or introduce such motif in-
stances, changing this distribution.
With genome-wide linkage maps in hand, positional cloning became the paradigm for
uncovering the molecular basis of traits. Such experiments identified linked regions, se-
quenced those regions in cases (subjects who have the trait) and controls (who do not), and
thereby identified the causal genes. The first success of this method was the discovery of
the mutation driving Huntington's disease [12].
Given the subsequent success of this method in uncovering the basis of Mendelian
traits arising from a single mutation/gene, geneticists hoped to be able to explain traits
like common diseases. They found Mendelian subtypes of some common diseases, but
the identified causal genes explained very few of the cases in the population. Indications
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Figure 2.2: Patterns of LD in the genomic region 5q31 [1]. Pairwise correlation is displayed
on the lower triangular matrix, where red is r2 - 1. Strong correlation (outlined in black)
demarcates blocks of nearby SNPs; however, we also observe long range correlations due
to limited recombination.
suggested these traits arise from many genes. Indeed, in 1910 East proposed common
traits are polygenic [6] and in 1919 Fisher proposed a model of how many discrete variants
could lead to continuous traits [11].
2.4 The common disease, common variants hypothesis
Model organism geneticists working on yeast and fly have the ability to construct large
crosses and therefore trace inheritance of complex polygenic traits and genetic variants
through large pedigrees. Human geneticists did not have this luxury; instead they turned
to insights from population and evolutionary genetics.
First, the human population has grown exponentially only recently on an evolution-
ary time scale. Evolutionary theory thus predicts limited genetic variation in the popu-
lation. Indeed, single nucleotide polymorphisms (SNPs) occur on average only once every
thousand base pairs. These naturally occurring DNA variants are single bases which take
multiple alleles (possibilities) in the population. Most of these variants only take one of two
alleles, called major and minor based on their relative frequency in the population. More-
over, the majority of these variants are common (i.e. the minor allele appears in more than
5% of the population).
Second, many Mendelian diseases arise from rare variants. These variants have large
effects on reproductive success, so evolutionary theory predicts selection will drive their
frequency to zero. On the other hand, common disease has smaller effect on reproductive
fitness and so variants causing such traits could arise to higher frequency in the popula-
tion. This outcome is facilitated by the recent growth in the human population. Moreover,
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rs6679677 AA AC CC
Controls 84 1902 8602
T1D Cases 62 541 1359
Table 2.1: Genotype counts for an example GWAS tag SNP. This SNP tags a locus known
to be associated with Type 1 Diabetes and shows a different distribution of counts in cases
than in controls. The p-value for a 2 degree of freedom chi-square test on this contingency
table is p = 6.5 x 10-39
in some cases heterozygotes (having one risk allele) for disease-causing variants have an
advantage over their homozygote counterparts (having no risk alleles). For example, sickle-
cell anemia heterozygotes show increased resistance to malaria. Thus, human geneticists
proposed common diseases arise from common variants.
2.5 Genome-wide association studies
To actually find common variants causing common disease in genome-wide association stud-
ies (GWASs), geneticists had to achieve three goals. First, they had to build comprehensive
catalogs of SNPs in the human population. The HapMap consortium has sequenced over
one thousand individuals and has published a catalog of over 2 million common SNPs
[39, 40, 41]. More recently, the Thousand Genomes Project consortium has sequenced a
comparable number of individuals using the latest sequencing technology and published
a catalog of 38 million SNPs including rare variants [37].
Second, they had to develop methods to quickly and cheaply genotype these variants
in large panels of individuals. Here, they were aided LD. As shown in Figure 2.2, SNPs
occur in large blocks in which no recombination has occurred. Thus the genotypes of
common SNPs can be inferred from just the genotypes of carefully chosen tag SNPs.
To actually genotype these tag SNPs, they developed DNA microarrays [44]. The
array itself is a large library of DNA fragments called probes with one end anchored to a
chip. The experiment amplifies and fragments the sample DNA, attaches fluorescent tags
to the fragments, and hybridizes the fragments to the probes. They recover the original
genotypes by observing the light intensity at each probe.
Third, they had to develop the statistics to analyze the patterns of genotypes in the
cohorts of cases and controls. At a basic level, GWAS performs one hypothesis test per
locus (a region of the genome represented by the tag SNP, but also containing all of the
common SNPs in LD with the tag). There are two frequently tested null hypotheses: the
distribution of allele counts is independent between cases and controls, or the distribution
of genotype counts is independent. Table 2.1 shows an example set up for testing the null
hypothesis the distributions of genotypes between controls and Type 1 Diabetes cases at a
particular tag SNP are independent. One issue is conducting millions of such tests inflates
the false positive rate and requires stringent correction. The usual method is Bonferroni
correction (dividing the desired false positive rate a by the total number of tests) which is
known to be over-conservative.
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A more difficult problem is accounting for sources of genetic variation which are
known to not be related to phenotype. One obvious confounder is familial relation be-
tween subjects, which violates the independence assumption underlying the statistical
testing. But another consequence of the recent human population expansion is genome-
wide allele frequency differences associated with ethnicity (i.e. human subpopulations).
One possible way to account for these biases is to simply choose subjects such that they
are unrelated and come from the same ethnic background. Statistically correcting for this
bias in cohorts of mixed ethnicities requires more sophisticated methods such as genomic
control, principal components analysis, or learning mixed models. Technical artifacts of
the genotyping technology are another unavoidable confounder, but the error rates of the
technologies are steadily decreasing.
2.6 The missing heritability problem
To date, thousands of loci have been associated with hundreds of traits [15]. Many of these
loci are independent, further supporting the polygenic basis of complex traits. However,
the vast majority do not lie in or near genes, making interpreting their function difficult.
Moreover, those variants which have been independently reproduced in follow-up stud-
ies still explain only a fraction of the heritability of these traits [23, 24, 8]. Heritability is
the proportion of phenotypic variation explained by genetic variation. Obviously, other
factors beyond genetics contribute to the instances of common disease in the population.
However, the fraction of heritability of common disease explained by known variants does
not match the fraction of heritability attributable to genetics based on tracing these diseases
through pedigrees.
There are multiple competing hypotheses about where this missing heritability can
be found. First, one previously inaccessible source is rare, private mutations. These are
not captured by DNA microarrays, but can be efficiently genotyped by current sequencing
technology. Second, another potential source is DNA structural variants, such as inser-
tions, deletions, inversions, repeats, and other rearrangements of the sequence. Again, it is
only with the latest technology that genome-wide detection of these variants has become
feasible.
Third, common variants could indeed explain the heritability of complex traits but
have too low individual effect sizes to be detected by current methods. One concern is that
the statistical power of genome-wide association studies is limited by the size of the case
and control cohorts. Some progress has been made on this front by pooling data across
studies and performing meta-analysis. Fourth, variants and genes interact with each other
non-additively to contribute to complex traits. Many computational models have been
proposed to learn such interactions from genotype data; however, they have to bound
the degree of interaction terms to make analysis tractable and still leave much heritability
unexplained.
Recent work on the genetic basis of human height lends weight to these last two hy-
potheses [30, 19]. Height is estimated to be 80% heritable. Although some rare variants
have been found which explain extreme values of the phenotype, they explain only a mi-
nority of cases. Roughly 50 SNPs have been associated with height in GWASs; however,
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they explain only 5% of the heritability. However, by considering the entire GWAS panel
of SNPs we can explain roughly 45% of the heritability of height.
2.7 Epigenetics
Parallel to these developments in understanding the role of DNA as genetic code and lo-
calizing causal variants for traits, we have also learned there is more to the molecule than
simply the primary sequence. In particular, there are heritable molecular traits which are
not explained by the primary sequence. One example is DNA methylation, in which indi-
vidual cytosine nucleotides are modified with an additional methyl (CH3) group. Methy-
lation is now known to serve as a silencer of DNA function, and current work seeks to
understand both how the primary sequence and disease traits can change methylation
across the genome.
Epigenetics also refers more generally to molecular factors other than the primary DNA
sequence which can affect traits. As described previously, the DNA molecule is divided
into chromosomes. The structure of chromosomes involves several nested levels of struc-
ture as shown in Figure 2.1. At the lowest level, the DNA double helix is wrapped around
protein complexes called nucleosomes, each constructed of four proteins called histones. His-
tones themselves are accepting of modifications such as methylation and acetylation. Hun-
dreds of these modifications, called chromatin marks, have been discovered experimentally,
leading to the hypothesis they also encode part of the function of DNA. For example,
H3K4Me3 (trimethylation of the 4th amino acid in histone 3) is associated with nearby
promoter activity.
Chromatin modifications are measured using chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-Seq). The experiment uses restriction enzymes frag-
ment the DNA. Specifically selected antibodies are used to select fragments bound to pro-
teins of interest (such as histones with a particular modification). The fragments are then
sequenced and aligned to a reference genome to localize their position.
We do not know a priori the function associated with individual marks, nor whether
they act independently. Ernst instead used an unsupervised approach to learn "chromatin
states", hidden states of a multivariate HMM [9]. The emission alphabet of the HMM is
combinations of chromatin marks; the hidden states correspond to biological functions
which change the probability of observing particular combinations. By learning the HMM
over the whole genome, we get a high resolution map of regions which are likely pro-
moters, enhancers, repressors, transcribed elements, etc. For example, Figure 2.3 shows
the annotation of the WLS gene across nine human cell types. This gene is important in
eukaryotic development in aligning one axis of symmetry. The gene is is predicted to be
transcribed (green) in five of the cell types. In those cell types, we find an active enhancer
(yellow). However, in the others the gene is quiescent (not expressed; gray). We find the
promoter is poised (purple): although transcription factors are bound to it the gene is not
being transcribed. Poised regulators are needed for rapid, time-dependent regulation of
genes which is necessary in the development of embryos.
Beyond wrapping around histones, the DNA molecule is further condensed into a
dense structure called chromatin. It is important to note the primary sequence is inacces-
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Scale 10 kb| | hg19
chr1 68,620,00d 68,625,004 68,630,004 68,635,00d 68,640,004 68,645,00d 68,650,00d 68,655,00d
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
UCSC Genes -- ---
Chromatin State Segmentation by HMM from ENCODE/Broad
GM12878 ChromHMMIU
H1-hESC ChromHMM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM,
HSMM ChromHMMIU
NHEK ChromHMM-
NHLF ChromHMM1
Figure 2.3: Chromatin state annotations of the region containing the WLS gene across nine
human cell types. The gene is expressed (green) in five of the cell types. In these cell types
we can identify a nearby strong enhancer (yellow). The promoter is poised (purple) but
the gene is inactive (gray) in the other cell types.
sible in regions which are so condensed, as shown in Figure 2.1. Thus, whether or not
chromatin is open is another indication of regulatory function. There are several exper-
imental approaches to identify open chromatin, such as DNAseI hypersensitivity (DHS)
and Digital Genomic Footprints (DGF) [14]. In essence, these methods all use restriction
enzymes to cut DNA where it is accessible, sequences the fragments, and aligns them to a
reference genome to localize their position.
Epigenetic modifications are an invaluable resource in interpreting the role of the non-
coding part of the genome. Towards this end, the ENCODE Consortium has produced
chromatin state maps of nine human cell lines and DHS/DGF in ninety [38]. The NIH
Roadmap Epigenomics Consortium has produced complete epigenomes of 85 primary
human cell types including methylation, gene expression (by extracting and sequencing
RNA), and chromatin state maps [2].
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Chapter 3
Genome-wide enrichments of
functional elements
We have introduced the paradigm of genome-wide association studies and described how
potentially many undiscovered loci could escape detection. We also introduced regulatory
elements which control gene expression and are known to play some role in disease. Now,
we describe our contributions in combining these data to identify large numbers of small
effect size, potentially causal variants.
3.1 Methods
3.1.1 Functional annotations
We use ChromHMM annotations for nine ENCODE cell lines downloaded from the UCSC
Genome Browser. We also use currently unpublished ChromHMM annotations for 85
Roadmap Epigenomics primary cell types (intersecting replicates) from the Analysis Work-
ing Group. We use DHS and DGF annotations for 90 ENCODE cell lines downloaded
from the UCSC Genome Browser. We use long poly-A+ RNA-Seq contigs in 9 ENCODE
cell lines to produce annotations of discretized expression downloaded from the European
Bioinformatics Institute (accessed through the UCSC ENCODE portal).
3.1.2 GWAS Data
We revisit the Wellcome Trust Case Control Consortium 7 Diseases studies [42]. These
studies investigate common diseases: bipolar disorder, coronary artery disease, Crohn's
disease, hypertension, rheumatoid arthritis, Type 1 Diabetes, and Type 2 Diabetes. Each
study involves a cohort of 2,000 cases and a shared set of 3,004 controls. All subjects were
of British descent and were chosen to be unrelated. The controls were taken from two
sources: the UK National Blood Service and the 1958 British Birth Cohort.
The cohorts were genotyped on the Affymetrix 500K SNP array, capturing just under
500,000 common SNPs. They were then imputed to the HapMap 3 common variants, yield-
ing genotypes for 2.6 million common SNPs. P-values were computed using a 1 degree of
freedom chi-square test for independence of allele counts between cases and controls.
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We focus on the GWAS for Type 1 Diabetes (T1D). This disease is a classical example
of a common, polygenic disease [13]. The disease pathology involves autoimmune de-
struction of beta cells in the pancreas which produce insulin. Those with the disease must
inject insulin into their bloodstream to maintain healthy levels of blood sugars.
There is a Mendelian subtype of T1D which is attributable to a single rare mutation;
however, this subtype explains fewer than 1% of cases in the population. Evidence sup-
ports the hypothesis hundreds of moderate-effect variants explain the disease making it
an ideal disease to study. Moreover, we have regulatory annotations for a large variety of
immune cells with various surface markers, giving us the opportunity to find regulators in
disease-relevant cell types. These regulators are more likely to have a role in the disease,
especially if they are specific to immune cells.
3.1.3 Statistical analysis
Our methods are motivated by two observations. First, the majority (roughly 80%) of trait-
associated variants which have been found to date fall outside of genes. One obvious ex-
planation is these variants fall in regulatory regions and contribute to disease mechanism
by disrupting gene regulation. Second, evidence suggests disease-associated variants have
moderate effect sizes which cannot be captured by current GWASs. They do not have large
enough sample sizes to have sufficient power to detect these variants.
In essence, we want to extend the notion of enrichment of top loci to the whole
genome. Specifically, we ask whether or not variants falling in regulatory regions are
skewed to have lower p-value than variants falling outside regulatory regions. To answer
this question we develop a visualization called an RR plot 1. We rank the SNPs in order of
increasing GWAS p-value and first compute the total number of SNPs falling in regulatory
regions ("hits"). Let T be this total number. As we traverse the list, we keep a running
count of how many hits we have observed and how many we would have expected as-
suming hits were uniformly distributed over the list. Suppose we have seen M of N total
SNPs. Then the expected count is equal to:
MT
E- N
N
Suppose in the M SNPs there were 0 SNPs observed to fall in regulatory regions. We
define the normalized cumulative deviation as:
D =0-E
T
We plot this quantity every 1000 SNPs down the list to obtain the RR plot. For exam-
ple, Figure 3.1 shows an RR plot for enhancers in CD4+ CD25~ IL17+ PMA/Ionomcyin-
stimulated Th17 primary cells in blue and an RR plot for a permuted control set of en-
hancers in red.
We make several key observations about these plots. First, the deviation is defined in
such a way that the plot starts and ends at zero deviation. Second, if p-values in regula-
tory regions are skewed to have lower p-values than those outside the RR plot will show
1a play on quantile-quantile (QQ) plot
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Figure 3.1: Example RR plot. After seeing 30K SNPs we have encountered 1.6K overlaps
with Th1 7 enhancers where only 900 were expected (based on the total count). When we
plot this deviation over the whole ranked list, Th17 enhancers (blue) are clearly enriched
compared to the randomized control regions (red).
larger deviation early in the ranked list. Third, the plots not only allow us to ask whether
functional regions are enriched for disease-associated variants but also how far down the
ranked list we have to go before we stop observing this enrichment. In particular, we focus
on the first part of the curve because although we hypothesize large numbers of variants
could contribute to disease we do not believe variants which are not even significant be-
fore multiple testing correction are relevant. Therefore, we focus on the first 150,000 SNPs,
beyond which p-values stop being significant at the a = .05 level.
3.1.4 Related work
There are several methods published to interpret top GWAS loci using regulatory anno-
tations. Ernst revisited published associations for diseases and showed in some cases
they overlap more than expected with enhancer regions [10]. Moreover, the implicated
enhancers and the genes they target are specifically active only in disease-relevant cell
types. For example, reported associations for systemic lupus erythematosis, an autoim-
mune disease, fall in GM12878 lymphoblastoid-specific enhancers (an immune cell type).
One of these associations tags a mutation which disrupts an Ets-1 sequence motif, which
disrupts the GM12878-specific activating transcription factor Ets-1. This SNP is therefore
hypothesized to disrupt activation of the targeted HLA-DRB1 gene, which is important for
recognition of cell surface markers and differentiating one's own cells from invaders.
Trynka used a similar approach to interpret top SNPs and strongly correlated vari-
ants in LD in four phenotypes [43]. However, rather than calling chromatin states their
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approach examined chromatin marks individually. The method computes a cell type-
specificity score by based on the distance to the nearest ChIP-Seq peak in each cell type. To
assess significance, the score is computed for LD block size-matched control sets.
Maurano used DHS and DGF to localize GWAS hits [25]. They first used cell type-
activity profiles to link DHS regions with their target genes. They next identified variants
falling in TF binding sites and showed they were over-represented in binding sites for
genes relevant to disease traits. They also proposed hypergeometric tests at increasing p-
value thresholds as a method to identify disease-relevant cell types. We do not take this
approach because it introduces another multiple testing problem.
The question of whether p-values falling in a set of regions are skewed to be lower
than those falling outside the set is a well-studied problem. In particular, this problem
formulation is known as the competitive null hypothesis in gene set enrichment analysis.
Gene set enrichment analysis is the problem of prioritizing sets of genes (usually related
by function) for further dissection. Typically, each gene is scored based on the p-value of
nearby SNPs either in terms of genomic position or correlation due to LD. The competitive
null hypothesis states the scores of genes in the gene set are the same as the scores of genes
outside the set. Our method differs from this approach by not assigning scores to regions
but rather computing statistics on the p-values of individual SNPs directly.
One obvious approach to answer this question in our setting is treating the two sets
of p-values as samples and using established statistical tests. The Mann-Whitney U test
is a nonparametric test of the null hypothesis the two samples are the same against the al-
ternative hypothesis one sample is greater than the other. U is defined as the sum for each
observation in the first sample of the number of observations in the second sample which
have lower rank. This quantity has a closed-form in terms of the sums of ranks of the ob-
servations in each sample. It is also approximately normally distributed. However, under
this formulation the test is equivalent to one which asks whether difference of the medians
of the two samples is nonzero [34]. This quantity does not capture the full distribution of
the p-values, making it inappropriate for answering the question we are interested in.
The Kolmogorov-Smirnov two-sample D test is a nonparametric test of the null hy-
pothesis the two samples come from the same probability distribution against the alter-
native hypothesis they do not. D is defined as a function of the empirical cumulative
distribution functions of the two samples. Critical values of D (needed to compute p-
values) are tabulated because the statistic does not have a closed-form distribution. This
test more directly answers the question of whether the p-values in the first sample (falling
in regulatory regions) are skewed to be different from those in the second sample (outside).
However, these two tests make independence assumptions which does not hold. First,
they assume individual observations are independent. However, the two samples are p-
values of SNPs and we know the genotypes of nearby SNPs are highly correlated due
to LD. Therefore, the patterns of genotypes across cases and controls and therefore the
p-values of nearby SNPs are also highly correlated.
Second, the they assume the two samples are independent. The patterns of genotypes
in regulatory variants across cases and controls will be different from the patterns of other
variants due to differential natural selection. Variants outside regulatory regions are less
likely to have a role in reproductive fitness and therefore selection is less likely to apply
pressure to maintain a particular genotype at those variants. On the other hand, variants
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in regulatory regions are more likely to have a role and therefore selection will reduce the
variability. Thus, the two samples are not independent because we gain some information
about the p-values by conditioning on whether or not the SNP they correspond to falls in
a regulatory region.
Statistical pitfalls aside, this approach produces easily interpreted results in identify-
ing which cell types and annotations are relevant. However, the resulting p-values do not
give any indication of how many SNPs are contributing to the observed enrichment.
A second approach is to ask whether variants falling in regulatory regions are over-
represented at the head of the ranked list. One obvious way to test this approach is to
compute Fisher's exact p-values at a variety of cutoffs; however, this method requires
further multiple testing correction.
Our approach of keeping a running deviation is used by a number of gene set en-
richment methods which we draw inspiration from. In particular, the GSEA algorithm
defines an enrichment score as the maximum value achieved by a walk down the ranked
list where each overlap counts as +1 and each non-overlap counts as -1 [36]. However,
GSEA makes the assumption few genes are involved in the trait and exponentially reduces
the weight of overlaps in the running sum further down the ranked list. We do not bias
our method in this manner in order to compute a new empirical cutoff beyond which we
stop seeing enrichment.
3.2 Results
3.2.1 Enhancer regions are enriched for disease-associated variants
We first ask which classes of functional regions are enriched for T1D-associated variants.
We compute RR plots for a variety of annotations in the GM12878 lymphoblastoid cell line:
" Promoter chromatin states
" Enhancer chromatin states
" Transcribed chromatin states
e Repressed chromatin states
e Other chromatin states
" Expressed regions (intersection of poly-A+ RNA-Seq contigs with transcribed chro-
matin states)
Figure 3.2 shows promoters, enhancers, transcribed regions, and expressed regions
are all enriched for T1D-associated variants. We expect transcribed and expressed regions
to be enriched because mutations in these regions are more likely to be non-synonymous
(changing an amino acid) and therefore deleterious. We also expect promoters to be en-
riched because mutations in these regions are more likely to disrupt binding sites which
are necessary for the transcription of proteins, directly affecting gene expression. More-
over, variants in promoters are more likely to be in LD with variants falling in the gene
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Figure 3.2: Enrichment of functional regions in GM12878 lymphoblastoid. We expect pro-
moters and expressed regions to be enriched for T1D-associated variants due to the ob-
vious role of these regions in cell function. However, we also find enhancer regions are
enriched suggesting disregulation plays a role in the disease.
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Figure 3.3: Comparison of enrichment of promoters and enhancers across cell types. Pro-
moters (left) are equally enriched in all cell types. In contrast, enhancers (right) show cell
type-specific enrichment in disease-relevant immune cell types.
they target meaning their p-values are more likely to be correlated and equally skewed.
However, we also find enhancers are enriched, suggesting distal regulation of genes plays
a significant role in the disease.
Next, we look at enrichment of these various functional classes across the ENCODE
and Roadmap cell types. Figure 3.3 shows promoters in all cell types are equally enriched
for T1D-associated variants. This result is supported by the fact promoters are conserved
across cell types, i.e. regions of the genome which are promoters in one cell type are also
highly likely to be promoters in another cell type. We find enrichment of promoters is
uninformative in picking out regulatory variants which are cell type-specific.
Unlike promoters, enhancers are dynamic across different cell types. They show much
greater variability in activity across cell types and are important in processes like cell type
differentiation. This fact suggests enrichment of enhancer regions should show more cell
type-specificity. Indeed, we find enhancers in T and B immune cell lines with a variety
of surface markers show the greatest enrichment of all cell types. These cell types are the
most relevant to the autoimmune nature of T1D out of those cell types for which we have
chromatin state annotations.
Another key observation to make is the number of SNPs to which the observed enrich-
ment continues past. We find enrichment of enhancers in immune cell lines even beyond
30,000 SNPs. This number is two orders of magnitude greater than the largest estimates
of the number of SNPs involved in complex traits such as height. One obvious question is
how many of these top 30,000 SNPs are actually involved in T1D. We can begin to answer
this question by first looking at how many of the top 30,000 SNPs actually fall in functional
regions. Table 3.1 shows these counts for functional regions in GM12878 lymphoblastoid.
Only roughly 2,000 of these SNPs fall in enhancers, and even fewer fall in promoters and
transcribed regions. But this result raises another question: why do we have to traverse
30,000 SNPs in the ranked list before we pick up all of the 2,000 the enhancers which could
contribute to the enrichment. One potential explanation is we pick up SNPs in LD with
causal variants as we walk down the ranked list and therefore dilute the signal.
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Region type Count (top) Count (genome)
Promoter 876 27641
Enhancer 2463 117406
Insulator 249 15631
Repressed 1848 86762
Transcribed 5566 337297
Other 18998 1870718
poly-A+ RNA-Seq 379 14085
Table 3.1: Counts of top T1D-associated variants in functional regions in GM12878 lym-
phoblastoid. In the top 30,000 variants, only a small fraction fall in promoters, enhancers,
or coding regions (either predicted by chromatin marks or actually expressed).
3.2.2 Implicated enhancers appear genome-wide
This concern about LD is significant because regulatory regions are physically clustered.
This fact follows naturally from the fact protein-protein interaction is the mechanism of
transcriptional regulation. Proteins bind to sequence motifs in regulatory regions, which
are close to each other either due to being close in terms of genetic (base pair) position or
being close to each other in three-dimensional position (because the DNA molecule folds
on itself). Variants which are nearby are in stronger LD and therefore their genotypes and
p-values are more highly correlated The concern then is the 2,000 enhancers we find are all
physically clustered and in LD with each other, so only a few of them are actually causal
and the rest simply have correlated p-value.
Another concern is the enhancers we find all fall in the Major Histocompatability Com-
plex (MHC). Although genome-wide association studies consider mutations all over the
genome, the top p-values are often highly localized to the MHC. This region of the genome
in chromosome 6 contains many genes related to the function of recognizing cell surface
markers to distinguish cells belonging to oneself versus cells which are invaders. It is
highly variable across individuals and human subpopulations due to its role in immune
response. It also shows atypical LD patterns compared to the rest of the genome such as
long-range LD (i.e., abnormally large blocks in which no recombination occurs). These
features of the MHC violate usual assumptions used in GWAS statistical testing and there-
fore variants in these regions often show highly significant p-values regardless of their
relevance to the trait in question. Although in the case of T1D we expect to find hits in the
MHC due to the autoimmune disease pathology, we also expect to find hits outside the
MHC.
To visualize where in the genome the hits cluster, we map individual chromosomes
to Hilbert curves. Hilbert curves are space filling curves defined by David Hilbert in 1891
which map the one-dimensional line to the two-dimensional plane [5]. The key property
of these curves we exploit is preservation of locality. If two points are close to each other on
the line, they will remain close to each other when mapped to the Hilbert curve. Although
the converse is not true (points which are far apart on the line may be mapped close to
each other on the Hilbert curve), we are mainly concerned about overlaps which are close
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Figure 3.4: Overlaps with GM12878 enhancers in the top 30,000 T D-associated variants
and rheumatoid arthritis-associated variants mapped to Hnbert curves. No more than half
the overlaps localize to the MHC (boxed). There are hundreds of independent clusters of
enhancers, including some specific to each disease.
to each other.
Figure 3.4 shows this visualization for top enhancers in both TiD and rheumatoid
arthritis (RA), another autoimmune disease. Indeed, we find a large cluster of roughly
half the hits in the MIC. However, the remainder of the hits are scattered all over the
genome in small clusters giving further evidence these enhancers are independent. More-
over, while we observe many clusters are shared between the two diseases, we also find
many clusters which are disease-specific. Although both TD and RA are autoimmune,
they attack different parts of the human body (pancreas versus connective tissue). Ac-
cordingly, disease-specific clusters of enhancers are potentially related to disease-specific
disregulation which causes differential pathology
3.2.3 Implicated enhancers are independent of known associated loci
Another concern is the enhancers we find are linked by LD to known loci and therefore
we are not actually finding novel associations. In the case of TD, 91 loci are listed in the
TFDBase as reliably associated with the disease [33]. To address this issue, we subtract
out these loci (considering tagged SNPs with r2 > .8) from foreground and background
and redo the analysis. We address whether these enhancers are linked to nearby genes
by subtracting out TSS-proximal regions. We account for linkage to non-synonymous
variants by subtracting out loci tagged by those variants (again requiring r2 > .8) We
also do the same for loci overlapping the MHC.
Figure 3.5 shows we continue to find enrichment of enhancers even after subtracting
out all of these potential confounders, although to a lower magnitude. We continue to
see separation of immune cell types from other cell types giving further evidence we are
finding novel associations.
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Figure 3.5: Enrichment of enhancers persists after
such as known loci, nearby genes, coding variants,
tinue to be separated from other cell types even up
subtracting out potential confounders
and the MHC. Immune cell types con-
to 30,000 SNPs.
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Figure 3.6: Generation of permuted enhancer tracks (orange) from real enhancer tracks
(blue). The permutation procedure samples from real elements and therefore preserves
their properties. Sampling is more likely to pick constitutive enhancers because they ap-
pear more often in the population of all elements, allowing us to investigate the contribu-
tion of these enhancers. We destroy the association between the identity of the cell type
and which enhancers are assigned to it and hypothesize permuted tracks will show less
enrichment than real tracks.
3.2.4 Implicated enhancers are cell type-specific
Next, we look at whether the enhancers we found are actually specific to the immune cell
types or are constitutive (constant across all cell types). We first permute elements across
cell types to generate 100 new randomized cell types as shown in Figure 3.6. We first
sample a total number of elements from the distribution of total number of elements across
real cell types, then sample that number of elements from all elements across all cell types.
We hypothesize the identity of which enhancers are in a specific cell type is the important
quality. Therefore, our permutation procedure destroys this quality while preserving other
properties of the elements (such as the distribution of their sizes and distances to the closest
gene).
Figure 3.7 shows RR plots computed for these permuted cell types. We find all of
the randomized cell types show moderate enrichment early in the ranked list suggesting
this quantity is the contribution of constitutive enhancers. However, the enrichment is of
lesser magnitude than the observed enrichment for actual cell types. This result suggests
when we look at real cell types we are finding enrichment beyond just that of constitutive
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Figure 3.7: Enrichment of permuted enhancer tracks. As in the case of promoters, per-
muted tracks show some enrichment in all cell types, suggesting they represent the contri-
bution of constitutive enhancers. However, the observed enrichment is less than that for
real enhancer tracks.
enhancers. Moreover, as in the case of promoters none of the cell types is separated from
the rest when considering enrichment of constitutive enhancers.
We next look at enhancer clusters. To perform the clustering, we sweep a line over
the concatenated genome. For each intersected enhancer, we take the union of enhancers
intersecting that enhancer across all the other cell types. For that region, we compute a
binary vector specifying whether the region overlaps an enhancer in each cell type. We
cluster these activity vectors using k-means clustering, iteratively picking optimal k. For
each cluster, we generate a new pseudo-cell type containing the regions corresponding to
the activity vectors assigned to that cluster.
Each cluster captures a set of enhancers which is specific to a set of cell types. Figure
3.9a shows for each cluster the cell types which the set of enhancers is active in. Red
indicates strong enhancer activity, orange weak, and purple poised activity. For example,
cluster 19 captures constitutive enhancers which are active in all cell types whereas cluster
5 captures enhancers which are active only in a small set of T helper and memory T cells.
Figure 3.8 shows the enrichment of these clusters for T1D-associated variants. We
find several clusters are enriched, showing clear separation from other clusters. As shown
in Figure 3.9b, the most enriched clusters are largely specific to immune cell types. One
cluster represents the contribution of constitutive enhancers and shows strong enrichment.
However, the cell type-specific clusters contain enhancers active in only two broad types
25
0.03
0.02-
o 16
0.00
-0.01
037500 75000 112500 150000
SNPs ranked by increasing p-value
Figure 3.8: Enrichment of enhancer clusters for T1D-associated variants. Several clusters
are clearly separated from the others. Moreover, we continue to see a greater magnitude
of enrichment persisting to tens of thousands of SNPs.
of cells. The first are memory T cells, which recognize and respond to invasion. The sec-
ond are T helper cells, which are initially programmable to respond to new invaders. After
encountering a new antigen (cell surface marker which can be used to -identify invaders),
they mature into either memory cells, effector cells which increase immune response when
exposed to the same antigen, or regulatory cells which decrease immune response. Mis-
classification of one's own cells and disregulation of the immune response at the tissue
level are central to autoimmune disorders such as T1D. These results suggest we are in-
deed finding enhancers which are specifically active in exactly the disease-relevant cell
types. They could play a role in disregulation at the molecular level, modulating the ex-
pression of important genes and function of important pathways which could give rise to
the observed tissue-level disregulation.
3.2.5 Open chromatin is enriched for disease-associated variants
We have chromatin states for 9 ENCODE cell types and 85 Roadmap cell types. However,
these cell types are still only a fraction of the full spectrum of human cell types. For other
cell types we do not have this rich annotation of regulatory activity. However, for 90 dif-
ferent ENCODE cell types we have experimental assays of open chromatin, another proxy
for regulatory activity. Specifically, we have annotations of DNAseI hypersensitive sites
(DHS) and Digital Genomic Footprints (DGF).
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Figure 3.10: Enrichment of open chromatin. Enrichment of DHS for T1D-associated vari-
ants clearly separates immune cell types from others (left). The higher resolution DGF im-
proves this separation (center). Intersecting DHS with ChromHMM enhancers improves
separation over just considering enhancers (right).
Figure 3.10 shows the enrichment of DHS and DGF for T1D-associated variants. Again
we find T helper cells and CD20+ B cells are enriched. However, we find these cell types
show greater separation from other irrelevant cell types. This result shows the importance
of having annotations for the most disease-relevant cell types. Moreover, we find that the
higher-resolution DGF annotation shows better separation between cell types, suggesting
increasing the resolution of regulatory annotations will increase our power to detect regu-
latory variants relevant to disease.
For a small number of cell types, we have both chromatin states and DHS, allowing us
to further refine the annotation. By intersecting enhancer regions with DHS, we get regions
which we are more confident have regulatory function. Indeed, we again find immune cell
types are increasingly separated from other cell types.
All of these results point to molecular level regulation (i.e., regulation of gene expres-
sion) as playing a role in Type 1 Diabetes. We find only enhancers in immune cell types
relevant to T1D show enrichment for T1D-associated variants. This enrichment persists
to tens of thousands of SNPs, suggesting the genetic architecture of T1D involves many
more common variants than previously thought. We separate the contribution of these
enhancers from the linked contributions of nearby genes and find it is indeed the regula-
tory regions which are contributing to the observed enrichment. Moreover, we separate
the contribution of constitutive enhancers from the contribution of enhancers specific to
the enriched cell types. We find it is precisely those enhancers specific to disease-relevant
immune cell types which show the strongest enrichment. Thus, these variants could con-
tribute to molecular level disregulation, which in turn gives rise to tissue level disregula-
tion of the immune response and the autoimmune disease pathology.
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Chapter 4
Pathway analysis
In the previous chapter we identified a large set of of variants which are associated with
disease in enhancer regions. Now we develop mechanistic hypotheses about how those
variants actually contribute to disease. In particular, we want to find gene pathways which
these variants and regions are over-represented in.
4.1 Methods
4.1.1 Region-based tests for enrichment of pathways
We use the Genomic Enrichments of Annotations Tool (GREAT) to test whether regula-
tory regions are over-represented in regulatory domains of genes [26]. We use the default
settings, which estimates the regulatory domain of a gene as 5 kb upstream and 1 kb down-
stream of the TSS, extended to a maximum of 1 Mb upstream. However, the GREAT web
service (http: / /great . st anf ord. edu) also uses some experimentally validated reg-
ulatory domains. It incorporates twenty gene ontologies and has been shown to produce
robust and specific results.
GREAT uses two tests for over-representation of input regions in regulatory domains.
The first is based on a binomial model. For a given ontology term, the parameter p is
the fraction of the genome covered by the regulatory domains of genes with that term.
The parameter n is the number of background regions (the foreground is required to be a
subset of the background). Then, the observed number of overlaps is Binom(n, p) and the
probability of observing at least that many overlaps can be computed using the probability
mass function.
The second test is based on a hypergeometric model. A 2 x 2 contingency table par-
titions genes into those with a given term and those without and genes whose regulatory
domain intersects an input region and those which do not. The observed counts follow the
hypergeometric distribution, for which a p-value can be computed using Fisher's exact
test. By computing both tests, GREAT separates truly enriched pathways from pathways
with highly enriched genes (which drives the binomial p-value down) or biased regulatory
domains (which drives the hypergeometric p-value down).
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4.1.2 SNP-based exact rank sum test for enrichment of pathways
We are also interested in identifying gene sets for which the associated variants are skewed
to have lower p-values. Rather than scoring and computing statistics on genes, we want
to annotate and compute statistics on variants. We assign each variant to the closest gene
because for most cell types we do not have gene expression data. We then ask for each
pathway in the Molecular Signatures Database [36] whether variants annotated with that
pathway are skewed to have lower p-value than variants which are not.
We previously described the application of the Mann-Whitney U and Kolmogorov-
Smirnov two-sample D tests to perform this analysis We also described how these tests are
inappropriate for answering this question due to the overly strong independence assump-
tions they make. In particular, variants which are close by are more strongly linked by LD
and therefore have more strongly correlated p-values. Also, variants which are close by
are more likely to be assigned the same pathway annotation.
Instead, we develop a permutation test based on the Mann-Whitney U test to compute
exact p-values. The test statistic itself is simply the sum of ranks of variants with the
pathway annotation. Suppose we have a vector of ranks r E Z" of variants arranged in
genomic order (concatenating chromosomes) and a vector of binary (0, 1) annotations a.
Then the statistic is:
X =r- a
The permutation procedure preserves the clustering properties of the p-values (ranks)
and annotations, but destroys the association between the two. For the ith rotation of the
vector a, we compute the statistic Xi in the same fashion. Then, the exact p-value is
1 n
p = 1(Xi < Xo)
4.1.3 Related work
There are two broad categories of pathway analysis: self-contained tests and competitive
tests [45]. The self-contained null hypothesis is the gene set is not associated with the phe-
notype. The competitive null hypothesis is the genes in a gene set are not more associated
with phenotype than genes not in the gene set. As in the previous chapter, we focus on the
competitive null hypothesis.
There are two main approaches for testing the competitive null hypothesis: gene-
based tests and SNP-based tests. We use a SNP-based approach, assigning gene ontology
terms to SNPs and computing statistics on SNPs. There are several SNP-based tests in
the literature. GSEA-SNP is based on GSEA and computes a similar running-sum enrich-
ment score based on walking down the ranked list of p-values [27]. The significance of
this score is computed using an exact test based on permuting phenotype labels, recom-
puting association p-values, and then recomputing the enrichment score. Unlike GSEA-
SNP, our method does not down-weight the contribution of SNPs as their rank increases.
Our method is also less computationally expensive than permuting phenotype labels.
SNPtoGO [4] and GESBAP [17] use Fisher's exact test to test the over-representation of
genes in a pathway at extreme ends of the ranked list. However, such a strategy requires
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one hypothesis test per cutoff and therefore more stringent multiple testing correction. We
only perform one hypothesis test per pathway-cell type combination.
4.2 Results
4.2.1 Enrichment of T1D-associated variants
We first asked which pathways are assigned SNPs with lower p-values. We approximated
the exact rank sum test by computing z-scores for the statistic computed under 1,000 ran-
domly chosen rotations of the annotation vector. However, only few pathways are signifi-
cantly enriched, and none remain after Benjamini-Hochberg FDR correction (FDR < .05).
4.2.2 Enrichment of enhancer regions
We next investigated whether enhancer regions were enriched for pathways. We used
GREAT to test enrichment of enhancer tracks in the 9 ENCODE and 90 Roadmap cell types
using the default settings (maximum extension of regulatory domains). GREAT failed to
complete using a background of all enhancer regions in all cell types, so we used the whole
genome as the background.
We restrict to the GO biological process terms. We throw out cell type-pathway com-
binations for which the FDR q-values for either the binomial and hypergeometric tests is
greater than .001, leaving 2,817 combinations. We clustered cell types and pathways inde-
pendently using hierarchical clustering with a Euclidean distance metric. Figure 4.1 shows
selected portions of the heatmap of enrichment for cell type-pathway combinations.
We find modest enrichment of a large number of pathways across all cell types. The
strongest enrichments are in a cluster of generic categories including transcriptional regu-
lation, macromolecular disassembly, and viral translation.
We expect transcriptional regulation to be enriched because we are considering en-
hancer regions. Macromolecular disassembly is a generic GO term which includes trans-
lational termination. Post-translational modification has been implicated in the develop-
ment of T1D autoimmune response [29]. We find further support for the enrichment of the
these categories in a cluster of enriched pathways in a cluster of immune cells. In particu-
lar, we find enrichment for the term protein modification by small protein conjugation.
We also find modest enrichment of relevant immune pathways in the top immune
cell types identified through genome-wide enrichments. Specifically, we find enrichment
for terms such as positive regulation of immune response, T cell activation, and leuko-
cyte activation. Moreover, we find enrichment for more specific terms such as immune
response-activating cell surface receptor signaling pathway.
4.2.3 Enrichment of TID-associated regulatory variants
Given enhancer regions are enriched for relevant high-level categories, we next asked
whether restricting to these regions could improve our SNP-based results. We used the
exact rank sum test against a background set of variants which fall in enhancer regions
31
0(2
I.n -U
77
Log fold enrichment
0.75
0.50
0.25
0.00
Cluster
Figure 4.1: Enrichment of enhancers for selected GO terms. Cell types and terms were
independently hierarchically clustered based on patterns of fold enrichment. We find large
blocks for terms related to transcription (top right), immune response (center right), and
post-transcriptional regulation (bottom right). We also find a cluster of Treg cell types with
various surface markers are enriched for all of these terms (left).
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in any cell type. We found few pathways were enriched after FDR correction. However,
those pathways were not obviously relevant to regulatory or disease function.
We then asked whether we could improve the region-based enrichment by restricting
to enhancers containing T1D-associated variants. We took the top 30,000 SNPs (our empir-
ical cutoff), and for each cell type used GREAT to test enrichment of only those enhancers
containing one of those top SNPs. We again restricted to cell type-pathway combinations
with binomial and hypergeometric q < .01, leaving 294 combinations. Figure 4.2 shows
when we consider this subset of disease relevant regulatory elements, we find a large clus-
ter of immune cell types is enriched in a large cluster of immune response-related GO
categories. In addition to the immune pathways found before we find 300-fold enrichment
for antigen processing and 30-fold enrichment for interferon gamma-mediated signaling
pathway. The gene PTPN2 which is associated with T1D is thought to modulate pancreatic
cell apoptosis in response to interferon gamma [28]. Pancreatic beta cells are responsible
for the production of insulin; their destruction is part of the known T1D pathology.
We again find a cluster of weaker enrichments in the top immune cell types for terms
positive regulation of T cell, leukocyte, and lymphocyte proliferation; B cell activation;
and positive regulation of immune response. However, we also find 4-fold enrichment for
regulation of interleukin production. Disregulation of the IL-2 pathway is a central defect
in T1D pathology [16]. Low dosage of IL-2 has been shown to offer protection from the
disease; however, high doses increase the autoimmune response.
They key observation here is we identified these pathways starting from non-coding
variants rather than coding variants. We know a large fraction of the top 30,000 T1D hits
are not near coding regions at all and therefore tag novel regulatory variants. We are
not merely recapitulating known T1D-relevant pathways in the literature by identifying
non-synonymous mutations in the genes contained in those pathways. Rather, we are
potentially identifying novel disease-relevant links in the regulatory networks of these
pathways.
4.2.4 Enrichment of enhancer clusters
Next, we asked whether enhancer clusters would show these same enrichments for spe-
cific terms. In the previous chapter we showed top T1D-associated variants were over-
represented in cell type-specific enhancers. The question is whether we gain anything by
starting from the variant associations instead of going straight to a priori disease-relevant
cell types.
Restricting to binomial and hypergeometric q < 1e8, we find 6,221 enriched cluster-
pathway combinations. These combinations show modest enrichments (order 10-fold) in
a variety of high level terms. Moreover, we do recapitulate pathways we found by using
top T1D SNPs to filter enhancers as shown in Figure 4.3. If we look specifically at the
clusters which showed enrichment for T1D-associated variants in the previous chapter,
we find many of the same enrichments for specific disease-relevant terms. However, the
fold enrichment is lower because the number and size of regions considered is higher.
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Figure 4.3: Enrichment of clustered enhancers for selected GO terms. Many cluster-
pathway combinations show just over 1 fold enrichment (not shown). The strongest en-
richments are again in a large cluster of immune response pathways, but they show rela-
tively low fold enrichment.
35
V
AE
Log fold enrichment
0.6
0.4
0.2
0.0
4.2.5 Enrichment of T1D-associated cell type-specific regulatory variants
Finally, we asked whether restricting to clustered regions containing T1D-associated vari-
ants could improve the enrichment. Restricting to binomial and hypergeometric q < .01,
we find 294 enriched cluster-pathway combinations. Figure 4.4 shows the heatmap of
enrichment for these combinations. We again find a large cluster of immune pathways en-
riched in clusters which are specifically active in immune cell types (although some show
weak activity in all cell types). Focusing on the enriched clusters identified in the previ-
ous chapter (Figure 3.9b), we find regions from the cluster showing constitutive activity
(19) does not show enrichment in any of these terms. However, regions from the immune
cell type-specific clusters are enriched for pathways involving leukocyte and T cell differ-
entiation, proliferation, and activation. We also find one cluster enriched for chromatin
modification, suggesting regulation of epigenetic modifications could also play a role in
the disease.
By starting from the empirical cutoff rather than from enriched clusters directly, we
also find some novel enrichments. For example, we find over 1,000-fold enrichment of the
term regulation of L-glutamate transport. L-glutamate is a known target of autoantibodies
associated with pancreatic beta cell destruction and onset of T1D [31] Again, by starting
from T1D-associated variants we find novel enrichments which suggest disruption of reg-
ulatory rather than coding function in disease-relevant pathways. This molecular level
disregulation in turn could give rise to disregulation of the immune response and the dis-
ease pathology.
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Figure 4.4: Enrichment of clustered enhancer regions containing top T1D-associated vari-
ants. a) Restricting to this subset of regions, we find much stronger enrichment for im-
mune pathways. We also find strong enrichment of L-glutamate transport, which we did
not find using any other set of regions. b) Focusing on clusters showing genome-wide
enrichment for T1D-associated variants identified in the previous chapter, we find the
immune-specific clusters show enrichment in more relevant pathways than the constitu-
tive cluster.
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Chapter 5
Discussion
The first goal of this thesis was to develop methods to identify common regulatory vari-
ants below the usual stringent GWAS p-value cutoffs. Towards this end, we developed
the RR plot visualization and exact ranksums test. The RR plot uses a novel definition
of cumulative deviation to separate enriched cell types from non-enriched cell types while
also allowing us to gauge an empirical p-value cutoff beyond which enrichment stops. The
exact ranksums test uses a novel permutation procedure (rotating vectors of annotations)
to preserve local clustering properties of the genome while destroying the association be-
tween regulatory regions and variants.
These methods have some weaknesses which future work needs to address. The defi-
nition of cumulative deviation is a nonstandard one which is harder to interpret at a glance.
In particular, the magnitude of deviation is not directly comparable between classes of
functional elements due to its dependence on the total number of overlaps. Moreover, the
magnitude is only comparable between cell types assuming there are roughly the same
number of overlaps per cell type (which does appear to be true). One natural alternative
statistic is fold enrichment; however, this statistic is also sensitive to the total number of
overlaps and is moreover highly variable early in the curve due to the small number of
SNPs seen.
To improve the interpretation of RR plots, we need to attach some notion of signif-
icance to the enrichment. One strategy for computing significance is to develop sets of
matched controls and recompute the curves for each control set. Control sets would match
the real overlaps for properties such as minor allele frequency, LD block size, and distance
to closest TSS. Based on the curves, we could compute z-scores for each point on the RR
plot, which are both directly comparable across features/cell types and easier to intuit sig-
nificance from. However, the major weakness of this strategy is we do not know a prior
which properties of the genome are necessary to match. Moreover, as the list of properties
grows the number of matching sets goes down, potentially reducing the number of unique
control sets which can be produced.
A more robust strategy is to permute phenotype labels, recompute association statis-
tics, and then recompute the curves. This approach produces a more obviously meaningful
null distribution. The trial we are computing a statistic over consists of generating a vector
of association statistics and then intersecting it with a vector of annotations. If we were
to actually repeat the trial, we would only generate a new vector of association statistics;
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everything else would remain constant. Moreover, this strategy automatically preserves
all properties of the genome since only phenotype labels change. However, this method is
more computationally expensive and also is sensitive to the choice of association statistic.
The second goal was to apply these methods to the WTCCC1 T1D GWAS and evalu-
ate their efficacy. Indeed, we find enrichment of enhancers persists to 30,000 top SNPs and
beyond, dwarfing usual estimates of the number of common variants involved in com-
plex disease by two orders of magnitude. Unlike enrichment of promoters, enrichment
of enhancers is highly dynamic across cell types and separates disease-relevant cell types
(immune cells) from irrelevant cell types. Moreover, this enrichment persists after correct-
ing for various confounders such as known T1D risk loci, nearby genes, non-synonymous
variants, and the MHC.
Surprisingly, of the top 30,000 SNPs, fewer than 2,000 actually fall in enhancer regions
in any single cell type. Even fewer fall in promoters and coding regions, raising the follow-
ing question: why do we have to consider 30,000 SNPs before enrichment stops when only
a small proportion of those SNPs have potential function? One possibility is non-robust
p-values disrupts the ranking of SNPs. The current lack of GWAS power due to sample
sizes and population genetic biases could cause such non-robustness. Another possibility
is these variants are functional in cell types whose epigenomes have not yet been profiled.
Future work in this area should address three concerns. First, we should attach sig-
nificance to the observed enrichments as described above.
Second, we should expand our catalog of common SNPs from HapMap 3 to Thousand
Genomes. This expansion requires re-imputation of the data to the Thousand Genomes ref-
erence panel. Thousand Genomes includes over double the common SNPs as HapMap. By
imputing to 5.6 million common SNPs, we increase the likelihood we find causal variants
directly instead of just tag SNPs.
Along these lines, we must also consider the role of rare, private mutations in disease
such as T1D. Imputation to the full Thousand Genomes panel is one step towards this goal.
On another front, the reduction in price of the latest generation of sequencing technologies
has made full genome sequencing and exome sequencing in large cohorts of cases and
controls possible. In particular, the Genetics of Type 2 Diabetes consortium has conducted
such a study in 2,700 individuals [18]. This study will not only give us unparalleled power
to detect causal variants, but will also give us the ability to query the genetic architecture
of complex disease. In particular, we can start to ask questions about the combinatorial
interaction of variants in disease, and learning functions which describe these interactions.
Third, we should apply these methods to larger cohorts with richer phenotyping. The
T1D Exchange (http: / /www. t ldexchange . org) is a non-profit organization bringing
together data on tens of thousands of patients across 65 American clinics. The data collec-
tion was designed specifically for downstream analysis aimed at identifying causal vari-
ants. Towards this end, patients are genotyped at high density in the MHC as well as
other relevant parts of the genome. They are also richly phenotyped for a large number of
metabolic and molecular traits as well as environmental and behavioral covariates. This re-
source will give us unparalleled power in our analyses, as well as the opportunity to study
problems such as improving the power of association by considering multiple correlated
phenotypes.
The third goal of this thesis was to interpret the function of the identified variants by
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identifying pathways they were enriched in. Using GREAT, we found enhancer regions
alone are already enriched for some disease-relevant pathways. However, by subsetting
to regions containing one of the top 30,000 T1D-associated SNPs, we found greater enrich-
ment in more specific GO terms. Moreover, by starting from associated variants falling
in regulatory regions, we specifically implicate regulatory mechanisms rather than coding
mutations.
Future work in this area should first investigate enrichment of transcription factor
motifs for T1D-associated variants. Preliminary work showed no enrichment for variants
falling in sequence motifs directly; however, current work shows enhancer regions con-
taining motifs are enriched for reported cardiovascular disease-associated loci. By apply-
ing our methods for genome-wide enrichment, we should be able to attach more specific
function to individual regions which we previously implicated.
Second, we should use expression data to link enhancers to the genes they target.
It is not clear what proportion of naive enhancer links (assigning to the closest gene) are
actually correct, which could severely impact the results of our SNP-based test for gene set
enrichment. GREAT makes the same assumptions about the regulatory domains of genes,
which may impact the region-based results as well. Instead, we should link enhancers to
gene targets by correlating enhancer activity across cell types with expression across cell
types. By using such higher confidence assignments we gain higher confidence hypotheses
about how variants in those regions affect gene pathways.
Third, we should study methylation as another potential mechanism by which vari-
ants affect gene expression. Methylation is associated with repression of genes, and it is
known that variants can affect methylation status. Recently, an epigenome-wide associ-
ation study found methylation mediates the association between genotype and rheuma-
toid arthritis (RA) [22]. Along these lines, we should correlate the regulatory regions and
pathways identified based on SNP associations in the WTCCC1 RA GWAS alone to those
identified by methylation associations for the same disease. By doing so, we can generate
more specific hypotheses about how non-coding variants contribute to complex disease.
We have begun to shed some light on the genetic architecture of complex disease,
but there is still much work to be done. In particular, we need to estimate the additional
heritability explained by the regulatory variants we have identified. The usual heritability
estimate involves studies of inheritance of the disease in cohorts of families; however, in
our case we do not have such data.
There are two types of approaches to estimating heritability from GWAS data directly.
The first is using restricted maximum likelihood estimation to fit a linear model from geno-
typic variance (characterized by a genetic relationship, or kinship, matrix) to phenotypic
variance [19]. When applied to the 500,000 genotype probes in the WTCCC1 T1D GWAS,
the model estimates the SNPs explain 37% of the variance in phenotype [21]. However,
the method is sensitive to confounding sources of genetic variation such as genotyping
error, population structure, and cryptic relatedness between individuals. This estimate is
obtained after throwing out over half the probes and one third of the samples and is a very
conservative estimate. A second approach learns a polygenic model to estimate heritabil-
ity [35]. When applied to T1D, it estimates 47% of the heritability is explained by common
SNPs.
These methods have additional pitfalls when applied to imputed data. In particu-
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lar, non-perfect LD (r2 < 1) affects the observed distribution of minor allele frequencies
and confounds estimates of genetic variance. One potential approach is to restrict to inde-
pendent tags and assign the union of annotations to these tags. However, this approach
assumes only one causal variant per locus which would be surprising if true.
There is a long road from studies of genetics to novel diagnostics and therapeutics.
However, the first step is identifying variants and generating hypotheses about their func-
tion. Interpreting GWAS has been the major challenge of the last 10 years. In parallel,
the study of epigenomics has shown the genome is rich in function beyond just the small
fraction which codes for proteins. This thesis contributes methods for combining genetic
and epigenetic data to generate hypotheses and the results of evaluating them on T1D. All
indications suggest the regulatory variants we have identified play a role in the disease
and could present novel diagnostic and treatment targets.
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